{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:42:06Z","timestamp":1775068926487,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.taap.2019.114857","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T08:40:25Z","timestamp":1576485625000},"page":"114857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells"],"prefix":"10.1016","volume":"387","author":[{"given":"Jing-Ting","family":"Chiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Sen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.114857_bb0005","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.taap.2019.114857_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.seminhematol.2014.05.008","article-title":"Targeting BCL2 for the treatment of lymphoid malignancies","volume":"51","author":"Anderson","year":"2014","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.taap.2019.114857_bb0015","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2019.114857_bb0020","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.taap.2019.114857_bb0025","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.taap.2019.114857_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-015-0132-6","article-title":"YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway","volume":"8","author":"Chang","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.taap.2019.114857_bb0035","first-page":"179","article-title":"Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter","volume":"3","author":"Cheng","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.taap.2019.114857_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2019.114857_bb0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2019.114857_bb0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2004.10.034","article-title":"Survivin expression in chronic myeloid leukemia","volume":"225","author":"Conte","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.taap.2019.114857_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1042\/BJ20110028","article-title":"The RNA-binding protein HuR stabilizes survivin mRNA in human oesophageal epithelial cells","volume":"437","author":"Donahue","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.taap.2019.114857_bb0060","doi-asserted-by":"crossref","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","article-title":"Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer","volume":"112","author":"Faber","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2019.114857_bb0065","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1541-7786.MCR-10-0325","article-title":"The RNA-binding protein HuR promotes glioma growth and treatment resistance","volume":"9","author":"Filippova","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.taap.2019.114857_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15548627.2016.1222992","article-title":"Emerging connections between RNA and autophagy","volume":"13","author":"Frankel","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.taap.2019.114857_bb0075","doi-asserted-by":"crossref","first-page":"e1412","DOI":"10.1038\/cddis.2014.379","article-title":"The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin","volume":"5","author":"Geserick","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2019.114857_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-012-1868-0","article-title":"The \u201csurvivin suppressants\u201d NSC 80467 and YM155 induce a DNA damage response","volume":"70","author":"Glaros","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2019.114857_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fchem.2019.00298","article-title":"Structure-activity relationship analysis of YM155 for inducing selective cell death of human pluripotent stem cells","volume":"7","author":"Go","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.taap.2019.114857_bb0090","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/onc.2015.264","article-title":"BIRC5\/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma","volume":"35","author":"Hagenbuchner","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2019.114857_bb0095","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/10428190500052131","article-title":"Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients","volume":"46","author":"Hern\u00e1ndez-Boluda","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2019.114857_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2015.09.026","article-title":"Antiproliferative, DNA intercalation and redox cycling activities of dioxonaphtho[2,3-d]imidazolium analogs of YM155: a structure-activity relationship study","volume":"104","author":"Ho","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.taap.2019.114857_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.taap.2017.08.019","article-title":"Quinacrine induces the apoptosis of human leukemia U937 cells through FOXP3\/miR-183\/\u03b2-TrCP\/SP1 axis-mediated BAX upregulation","volume":"334","author":"Huang","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2019.114857_bb0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.taap.2019.114857_bb0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neo.2015.07.003","article-title":"Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner","volume":"17","author":"Kiprianova","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.taap.2019.114857_bb0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.phrs.2017.04.006","article-title":"YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma","volume":"120","author":"Kojima","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.taap.2019.114857_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2018.06.019","article-title":"ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells","volume":"432","author":"Lee","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.taap.2019.114857_bb0130","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1073\/pnas.1406425111","article-title":"Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak","volume":"111","author":"Lindqvist","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2019.114857_bb0135","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jcp.22180","article-title":"Caffeine induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in human leukemia U937 cells via Ca2+\/ROS-mediated suppression of ERK\/c-fos pathway and activation of p38 MAPK\/c-jun pathway","volume":"224","author":"Liu","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2019.114857_bb0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1091\/mbc.E15-01-0028","article-title":"Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death","volume":"27","author":"Morciano","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.taap.2019.114857_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038625","article-title":"YM155 induces EGFR suppression in pancreatic cancer cells","volume":"7","author":"Na","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2019.114857_bb0150","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","article-title":"Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models","volume":"102","author":"Nakahara","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.taap.2019.114857_bb0155","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.febslet.2010.07.018","article-title":"Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis","volume":"584","author":"Niu","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.taap.2019.114857_bb0160","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.taap.2019.114857_bb0165","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.taap.2019.114857_bb0170","first-page":"202","article-title":"Survivin and YM155: how faithful is the liaison?","volume":"1845","author":"Rauch","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2019.114857_bb0175","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.taap.2019.114857_bb0180","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jop.12299","article-title":"YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines","volume":"44","author":"Sachita","year":"2015","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.taap.2019.114857_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/792639","article-title":"Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?","volume":"2011","author":"Son","year":"2011","journal-title":"J. Signal Transduct."},{"key":"10.1016\/j.taap.2019.114857_bb0190","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/1535-7163.MCT-12-0550","article-title":"Suppression of survivin induced by a BCR-ABL\/JAK2\/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs","volume":"12","author":"Stella","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2019.114857_bb0200","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bcp.2011.07.064","article-title":"Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263","volume":"82","author":"Tang","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2019.114857_bb0205","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2019.114857_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/524308","article-title":"The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias","volume":"2012","author":"Tzifi","year":"2012","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.taap.2019.114857_bb0215","doi-asserted-by":"crossref","first-page":"e2410","DOI":"10.1038\/cddis.2016.257","article-title":"Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance","volume":"7","author":"Voges","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2019.114857_bb0220","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1038\/sj.onc.1207556","article-title":"Mitogen-activated protein kinases in apoptosis regulation","volume":"23","author":"Wada","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2019.114857_bb0225","doi-asserted-by":"crossref","first-page":"10237","DOI":"10.18632\/oncotarget.2529","article-title":"Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1","volume":"5","author":"Wagner","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2019.114857_bb0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2010.12.007","article-title":"Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells","volume":"302","author":"Wang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.taap.2019.114857_bb0235","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-13-98","article-title":"The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.taap.2019.114857_bb0240","doi-asserted-by":"crossref","first-page":"61520","DOI":"10.18632\/oncotarget.11137","article-title":"YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-\u03baB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells","volume":"7","author":"Woo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2019.114857_bb0245","doi-asserted-by":"crossref","first-page":"e1771","DOI":"10.1038\/cddis.2015.139","article-title":"Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma","volume":"6","author":"Zhang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2019.114857_bb0250","doi-asserted-by":"crossref","first-page":"18445","DOI":"10.18632\/oncotarget.4315","article-title":"YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X1930465X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X1930465X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:49:19Z","timestamp":1758574159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X1930465X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"alternative-id":["S0041008X1930465X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.114857","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.114857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114857"}}